NANO Nuclear Energy Inc. Figure 1 - NANO Nuclear Energy Celebrates KRONOS MMR™ Micro Modular Reactor Event at The University of Illinois Urbana-Champaign. The event also featured remarks from NANO Nuclear’s executive management, senior U of I leadership, representatives from engineering, construction and commercial stakeholders and former U.S. Military Leaders. Credit to Heather Coit/Illinois Grainger Engineering. NANO receives support from key stakeholders for prototype project, including announcement ...

SÃO PAULO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teads (NASDAQ: TEAD), the omnichannel outcomes platform for the Open Internet, today announced the appointment of Fernando Tassinari as Managing Director of LATAM, effective immediately. This strategic leadership addition reinforces Teads’ commitment to accelerating growth across key Latin American markets, expanding its branding and performance business, and strengthening its position as one of the world’s leading digital advertising platforms. With more than tw ...

CFO Sandra Haskins announces retirement after 23 years of leadership and financial excellenceEDMONTON, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended September 30, 2025. Strategic highlights Executed a new long-term contract for Midland Cogeneration Venture (MCV)2 through to 2040, with improved economic terms, adding 10 years of incremental contracted revenueCommissioned 170 MW of battery storage in Ontario contracted th ...

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is advancing its first-in-class PP2A inhibitor, LB-100, and will present at the Spartan Capital Investor Conference 2025, highlighting its potential in cancer therapy [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new avenues for cancer drug development [3]. - The lead compound, LB-100, has shown to be well-tolerated in cancer patients and has the potential to enhance the effectiveness of existing chemotherapies and immunotherapies [3][4]. Product Development - LB-100 is part of a novel approach in cancer biology known as activation lethality, which is aimed at creating a new treatment paradigm [4]. - Clinical trials for LB-100 are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [4].

WINDSOR, Ontario, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NEXE Innovations Inc. (“NEXE”, the “Company”, "we", or "our") (TSX.V: NEXE) (Frankfurt: NX5) (OTC: NEXNF), a company focused on compostable materials and sustainable coffee solutions, announced today that it has received a repeat purchase order for ~250,000 BPI-certified compostable coffee pods from a North American office coffee services (OCS) and retail distributor. This follows an earlier delivery of 80,000 compostable coffee pods for three new SKUs on ...

Feedonomics customers benefit from data optimized for and exported to key AI channels. Select BigCommerce customers can now access agentic checkout with PayPal's agentic commerce servicesAUSTIN, Texas, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and AI-enriched product feed management solution Feedonomics, today announced a new agentic commerce feature with seamless agentic ...

MILPITAS, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- TurnOnGreen, Inc. (OTC: TOGI) (“TurnOnGreen” or the “Company”) and its power solutions subsidiary, Digital Power Corporation (“DPC”), today announced a major expansion of their telecommunications power product line, highlighted by a significant order from a global leader in network connectivity infrastructure. The order covers advanced power systems engineered for broadband, cable TV network, and data center applications, underscoring DPC’s growing presenc ...

Core Insights - Legend Biotech Corporation will host a conference call on November 12, 2025, at 8:00 am ET to discuss its third quarter 2025 results [1] - The company is a leader in cell therapy, particularly known for its CAR-T cell therapy product, CARVYKTI, for treating relapsed or refractory multiple myeloma [3] Company Overview - Legend Biotech employs over 2,800 individuals and is recognized as the largest standalone cell therapy company [3] - The company collaborates with Johnson & Johnson to develop and market CARVYKTI, aiming to enhance patient access and therapeutic potential [3] - Legend Biotech is focused on expanding its leadership in the cell therapy sector and driving future innovations across its pipeline [3]

Core Insights - Immutep Limited is advancing its clinical trials for eftilagimod alfa (efti) in oncology and autoimmune diseases, with significant progress reported in multiple trials [2][3][31] Oncology Development Programs - The TACTI-004 (KEYNOTE-F91) Phase III trial for advanced non-small cell lung cancer (NSCLC) is ongoing, with over 100 clinical sites activated across 24 countries, aiming to enroll approximately 756 patients [3][4] - The trial has successfully enrolled and randomized over 170 patients, surpassing the number required for a futility analysis, which is expected to be completed in Q1 CY2026 [6] - Positive feedback from the FDA has been received regarding the late-stage clinical development of efti for head and neck cancer patients with low PD-L1 expression [9][11] - The INSIGHT-003 Phase I trial is also evaluating efti in combination with KEYTRUDA® and chemotherapy for non-squamous NSCLC, with data presented at ESMO 2025 [7][8] Soft Tissue Sarcoma and Breast Cancer Trials - The EFTISARC-NEO Phase II trial for soft tissue sarcoma has met its primary endpoint, showing significant tumor hyalinization compared to historical data [16] - The AIPAC-003 trial for metastatic breast cancer has enrolled 71 patients, with ongoing follow-up and data analysis expected to be reported at the San Antonio Breast Cancer Symposium in December 2025 [17][19] Financial Position - As of September 30, 2025, Immutep reported a strong cash position of approximately A$109.85 million, consisting of A$83.41 million in cash and cash equivalents and A$26.44 million in term deposits [27] - The net cash used in R&D activities during Q1 FY26 was A$15.83 million, reflecting increased clinical trial activities [28] Intellectual Property Developments - Immutep was granted four new patents during the quarter, enhancing its intellectual property portfolio related to LAG-3 and its therapeutic applications [24]

MIAMI, NEW YORK and WASHINGTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Siebert Financial Corp. (NASDAQ: SIEB) today announced the opening of a Washington, D.C. office to support its expanding Capital Markets and Investment Banking team. Located at 3000 K Street, N.W., Suite 245, Washington, D.C., the new office will be led by Daniel M. Ondeck, Head of Institutional Sales, who works closely with Siebert’s investment bankers on origination and execution across public and private markets, as well as by newly appoin ...